Literature DB >> 29223797

Clinical impact of adjuvant radiation therapy delay after neoadjuvant chemotherapy in locally advanced breast cancer.

Saulo Brito Silva1, Allan Andresson Lima Pereira1, Gustavo Nader Marta2, Kennya Medeiros Lopes de Barros Lima1, Thiago Brasileiro de Freitas1, Adriana Reis Brandão Matutino1, Manoel Carlos Leonardi de Azevedo Souza1, Renata Gondim Meira Velame de Azevedo1, Pedro Antonio Hermida de Viveiros1, Julianne Maria da Silva Lima1, José Roberto Filassi3, Heloísa de Andrade Carvalho1, José Roberto Morales Piato3, Max S Mano4.   

Abstract

BACKGROUND: and Purpose: Post-operative radiation therapy (PORT) is usually indicated for patients with breast cancer (BC) after neoadjuvant chemotherapy (NAC) and surgery. However, the optimal timing to initiation of PORT is currently unknown.
MATERIAL AND METHODS: We retrospectively evaluated data from patients with BC who received PORT after NAC and surgery at our institution from 2008 to 2014. Patients were categorized into three groups according to the time between surgery and PORT: <8 weeks, 8-16 weeks and >16 weeks.
RESULTS: A total of 581 patients were included; 74% had clinical stage III. Forty-three patients started PORT within 8 weeks, 354 between 8 and 16 weeks and 184 beyond 16 weeks from surgery. With a median follow-up of 32 months, initiation of PORT up to 8 weeks after surgery was associated with better disease-free survival (DFS) (<8 weeks versus 8-16 weeks: HR 0.33; 95% CI 0.13-0.81; p = 0.02; <8 weeks versus >16 weeks: HR 0.38; 95% CI 0.15-0.96; p = 0.04) and better overall survival (OS) (<8 weeks versus 8-16 weeks: HR 0.22; 95% CI 0.05-0.90; p = 0.036; <8 weeks versus >16 weeks: HR 0.28; 95% CI 0.07-1.15; p = 0.08).
CONCLUSION: PORT started up to 8 weeks after surgery was associated with better DFS and OS in locally-advanced BC patients submitted to NAC. Our findings suggest that early initiation of PORT is critically important for these patients. However, the low numbers of patients and events in this study prevent us from drawing firm conclusions.
Copyright © 2017 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Breast neoplasms; Chemotherapy; Disease-free survival; Overall survival; Radiation therapy; Time-to-treatment

Mesh:

Year:  2017        PMID: 29223797     DOI: 10.1016/j.breast.2017.11.012

Source DB:  PubMed          Journal:  Breast        ISSN: 0960-9776            Impact factor:   4.380


  7 in total

1.  The impact of the time to start radiation therapy on overall survival in newly diagnosed glioblastoma.

Authors:  Vanessa Montes Santos; Gustavo Nader Marta; Marcella Coelho Mesquita; Rossana Veronica Mendoza Lopez; Edla Renata Cavalcante; Olavo Feher
Journal:  J Neurooncol       Date:  2019-03-08       Impact factor: 4.130

2.  Management of non-invasive tumours, benign tumours and breast cancer during the COVID-19 pandemic: recommendations based on a Latin American survey.

Authors:  G Luis Pendola; Roberto Elizalde; Pablo Sitic Vargas; José Caicedo Mallarino; Eduardo González; José Parada; Mauricio Camus; Ricardo Schwartz; Enrique Bargalló; Ruffo Freitas; Mauricio Magalhaes Costa; Vilmar Marques de Oliveira; Paula Escobar; Miguel Oller; Luis Fernando Viaña; Antonio Jurado Bambino; Gustavo Sarria; Francisco Terrier; Roger Corrales; Valeria Sanabria; Juan Carlos Rodríguez Agostini; Gonzalo Vargas Chacón; Víctor Manuel Pérez; Verónica Avilés; José Galarreta; Guillermo Laviña; Jorge Pérez Fuentes; Lía Bueso de Castellanos; Bolívar Arboleda Osorio; Herbert Castillo; Claudia Figueroa
Journal:  Ecancermedicalscience       Date:  2020-10-06

3.  Patterns of post-operative irradiation in breast cancer patients submitted to neoadjuvant chemotherapy.

Authors:  Kennya Medeiros L de B Lima; Allan A Lima Pereira; Thiago B de Freitas; Saulo Brito Silva; Heloisa de Andrade Carvalho; Max S Mano; Gustavo Nader Marta
Journal:  Rep Pract Oncol Radiother       Date:  2018-11-28

4.  Oral Administration of Prunella vulgaris L Improves the Effect of Taxane on Preventing the Progression of Breast Cancer and Reduces Its Side Effects.

Authors:  Jixue Zhao; Degang Ji; Xujie Zhai; Lirong Zhang; Xiao Luo; Xin Fu
Journal:  Front Pharmacol       Date:  2018-08-03       Impact factor: 5.810

5.  High expression of survivin predicts poor prognosis in cervical squamous cell carcinoma treated with paclitaxel and carboplatin.

Authors:  Yunzhong Zhang; Hong Yan; Ruiping Li; Yuzhen Guo; Rongfang Zheng
Journal:  Medicine (Baltimore)       Date:  2019-05       Impact factor: 1.817

6.  Treatment times in breast cancer patients receiving neoadjuvant vs adjuvant chemotherapy: Is efficiency a benefit of preoperative chemotherapy?

Authors:  Nicole M Melchior; Darren B Sachs; Gabrielle Gauvin; Cecilia Chang; Chihsiung E Wang; Elin R Sigurdson; John M Daly; Allison A Aggon; Shelly B Hayes; Elias I Obeid; Richard J Bleicher
Journal:  Cancer Med       Date:  2020-02-25       Impact factor: 4.452

7.  The impact on clinical outcomes of post-operative radiation therapy delay after neoadjuvant chemotherapy in patients with breast cancer: A multicentric international study.

Authors:  Gustavo Nader Marta; Reem AlBeesh; Allan A Lima Pereira; Leandro Jonata Oliveira; Max S Mano; Tarek Hijal
Journal:  Breast       Date:  2020-08-29       Impact factor: 4.380

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.